Projecting Expenditure on Medicines in the UK NHS
Expenditure on medicines is a readily identifiable element of health service costs. It is the focus of much attention by payers, not least in the UK even though the cost of medicines represents less than 10 % of total UK National Health Service (NHS) expenditure. Projecting future medicines spending enables the likely cost pressure to be allowed for in planning the scale and allocation of NHS resources. Simple extrapolations of past trends in expenditure fail to account for changes in the rate and mix of new medicines becoming available and in the scope for windfall savings when some medicines lose their patent protection. The objective of this study is to develop and test an improved method to project NHS pharmaceutical expenditure in the UK for the period 2012–2015.
We have adopted a product-by-product, bottom-up approach, which means that our projections are built up from individual products to the total market. Our projections of the impact of generic and biosimilars entry on prices and quantities of medicines sold, and of the rate of uptake of newly launched medicines, have been obtained from regression analysis of UK data. To address uncertainty, we have created a baseline and two other illustrative scenarios. We have compared our projections with actual expenditure for 2012.
Our projections estimate that, between 2011 and 2015, with no change in policy or price regulation, the UK total medicines bill would increase at an average compound annual growth rate (CAGR) of between 3.1 and 4.1 %. Total NHS spending on branded medicines and total NHS spending on generics are projected to increase at average CAGRs of 0.5–1.8 and 10.0–11.0 %, respectively, over the same time period. For the total market, the actual growth rate for 2012 lay within our projected range.
Our methodology provides a useful framework for projecting UK NHS medicines expenditure over the medium term and captures the impacts of existing medicines losing exclusivity and of new medicines being launched onto the market.
- 1.Hawe E, Yuen P, Baillie L. OHE guide to UK health and health care statistics. London: Office of Health Economics; 2011.Google Scholar
- 2.EFPIA. Statistics tables. Brussels: The European Federation of Pharmaceutical Industries and Associations; 2013.Google Scholar
- 5.Richards M (2012) Extent and causes of international variations in drug usage. A report for the Secretary of State for Health, London.Google Scholar
- 10.Mestre-Ferrandiz J. El mercado de medicamentos genéricos: regulación ‘versus’ competencia. ¿Qué podemos aprender de la experiencia internacional? Spanish. J Health Econ. 2007;6(1):33–6.Google Scholar
- 13.Connor P, Alldus C, Ciapparelli C, Kirby L. Long-term pharmaceutical forecasting: IMS Health’s experience. J Bus Forecast. 2003;22(4):10–5.Google Scholar
- 16.IMS (2013) World review executive. London: IMS Health.Google Scholar
- 17.Lloyd D. Prescriptions dispensed in the community: England, statistics for 2001 to 2011. London: The Health and Social Care Information Centre; 2011.Google Scholar
- 20.ABPI and DH (The Association of the British Pharmaceutical Industry and Department of Health) (2008) The Pharmaceutical Price Regulation Scheme 2009. London: Department of Health. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_098498.pdf. Accessed 20 March 2013.
- 21.Department of Health (2011) A new value-based approach to the pricing of branded medicines—government response to consultation. London: Department of Health.Google Scholar
- 22.DH (Department of Health) (2012) The cancer drugs fund—guidance to support operation of the cancer drugs fund in 2012–13. London: Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_133682. Accessed 20 March 2013.
- 23.Chauhan D, Towse A, Mestre-Ferrandiz J (2008) The market for biosimilars: evolution and policy options. OHE briefing (45). London: Office of Health Economics.Google Scholar
- 24.Rickwood S, Iervolino A. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. London: IMS Health; 2011.Google Scholar
- 25.Rovira J, Espin J, Garcia L, Orly de Labry A (2011) The impact of biosimilars’ entry in the EU market. Report prepared for the EC (DG Enterprise and Industry). http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf. Accessed 9th July 2011.
- 27.Höer C, Häussler B, Haustein R. Saving money in the European healthcare systems with biosimilars. Gen Biosimilars Initiative J (GaBI J). 2012;1(3–4):120–6.Google Scholar
- 28.Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S, Schacht A. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev Drug Discov. 2010;9(3):203–14.Google Scholar
- 29.DH and ABPI (Department of Health and The Association of the British Pharmaceutical Industry) (2002) PPRS: the study into the extent of competition in the supply of branded medicines to the NHS, component 3: competition in the out-of-patent sector. London: Department of Health. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH_5024085. Accessed 20 March 2013.
- 31.Mellstedt H. The future of biosimilars. Hosp Pharm Europe. 2010;49:33–3.Google Scholar
- 33.Rovira J, Espin J, Garcia L, Orly de Labry A (2011) The impact of biosimilars’ entry in the EU market. Report prepared for the EC (DG Enterprise and Industry. Granada: Andalusian School of Public Health. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf. Accessed 10th Dec 2012.